Linda M. Randolph, MD, is a Clinical Associate Professor in the Department of Pediatrics at the University of Southern California (USC). Her work focuses on medical genetics, neonatal care, and pediatric genetic disorders. She is affiliated with Children’s Hospital Los Angeles (CHLA), where she contributes to clinical and translational research in areas such as genetic diagnostics, prenatal screening, and the management of congenital disorders. Her research emphasizes leveraging genomic technologies—such as exome sequencing and deep learning—for early diagnosis and treatment of conditions like mucopolysaccharidosis, mitochondrial disorders, and neurofibromatosis. She has also investigated chimerism in twins and the clinical implications of genetic variants in pediatric populations. Key contributions include studies on the economic evaluation of early exome sequencing, the application of machine learning in facial dysmorphology analysis, and the correlation between genetic mutations and clinical phenotypes. Her work bridges basic science and clinical practice to improve outcomes for children with rare genetic conditions. Dr. Randolph’s publications span over two decades, reflecting her sustained engagement in pediatric genetics, prenatal diagnosis, and the intersection of genetic medicine with emerging technologies. She has collaborated on projects addressing thalassemia management, twin discordance, and the teratogenic effects of medications.
Alexandre G. Maia, Ph.D., is an Associate Professor in the Department of Laboratory Medicine and Pathology and Assistant Professor of Pharmacology at Mayo Clinic in Rochester, Minnesota. He serves as Senior Associate Consultant II-Research in the Division of Experimental Pathology and Laboratory Medicine and is the Associate Director of the Epigenomics Program at the Center for Individualized Medicine. Dr. Maia leads the Functional Epigenomics Laboratory, focusing on cutting-edge research in cancer and stem cell biology. Education: Postdoctoral Fellowship in Chromatin Biology, Icahn School of Medicine at Mount Sinai Ph.D. in Molecular Biology, University of Coimbra Predoctoral Research Fellow, University of California at San Francisco (UCSF) B.S. in Aquatic Sciences, ICBAS, University of Porto Undergraduate Studies, University of Rome (La Sapienza) Dr. Maia's research is centered on understanding the epigenomic regulation of cancer stem cells, particularly in ovarian cancer. His work integrates single-cell sequencing technologies such as ATAC-seq and RNA-seq to profile enhancer elements and transcriptional dependencies. He employs advanced model systems including 3D organoids, patient-derived xenografts, and liquid biopsies to study tumor heterogeneity. His lab utilizes CRISPR/Cas9 for functional validation and microfluidic devices for drug combination testing. Bioinformatic analysis of multi-omics data is a key component of his research. The recent publications reflect a strong trend in functional genomics, epigenetics, and personalized cancer therapy. His work spans multiple myeloma, clonal hematopoiesis, post-translational modifications, CAR T cell exhaustion, and personalized drug testing in pancreatic cancer. The recurring themes include single-cell multiomics, enhancer biology, and translational applications in oncology. Scientific Awards and Honors: Career Enhancement Program Award, Breast SPORE, Mayo Clinic (2022–2024) Early-Career Investigator, Ovarian Cancer Academy, U.S. Department of Defense (2021–2025) Regenerative Sciences Curriculum Development Award, Mayo Clinic (2020) Career Enhancement Program Award, Ovarian SPORE, Mayo Clinic (2019–2020) Career Development Award, Department of Laboratory Medicine and Pathology (2018) NYSCF-Druckenmiller Fellowship (2014–2017) Postdoctoral Recognition Award, Icahn School of Medicine (2014) Ph.D. Fellowship, Science and Technology Foundation, Portugal (2003–2007) Dr. Maia has received substantial grant support from prestigious programs including the Department of Defense Breast and Ovarian Cancer SPOREs, and has been recognized with multiple early-career awards. He mentors research trainees and contributes to curriculum development in regenerative sciences. His laboratory actively collaborates across disciplines to advance epigenomic technologies and their clinical applications. Dr. Maia leads the Functional Epigenomics Laboratory and plays a key role in the Epigenomics Program at the Center for Individualized Medicine. His team integrates wet-lab experimentation with computational biology to develop novel approaches for cancer diagnosis and therapy.
Marc Lütgehetmann, Dr. med., is a prominent researcher at the Institute of Medical Microbiology, Virology and Hygiene at the University Medical Center Hamburg-Eppendorf. With over 250 publications to his name, his work spans multiple areas of virology, microbiology, and infectious diseases diagnostics. His research has significant clinical implications, particularly in the areas of hepatitis viruses, transplant medicine, and emerging infectious diseases. Dr. Lütgehetmann's research interests primarily focus on viral pathogens including hepatitis viruses (HEV, HDV, HBV), SARS-CoV-2, HIV, and other emerging pathogens. His work combines laboratory research with clinical applications, particularly in developing and validating diagnostic methods. He has made significant contributions to understanding viral pathogenesis, immune responses to viral infections, and the development of molecular diagnostic techniques for various infectious diseases. His recent publications demonstrate a strong focus on diagnostic methodologies, including adaptation of high-throughput PCR systems, cell-free DNA sequencing for infection detection, and evaluation of commercial diagnostic panels. The research output shows a clear trajectory toward improving diagnostic accuracy and clinical utility in managing infectious diseases, particularly in immunocompromised patients and transplant recipients. Dr. Lütgehetmann collaborates extensively with researchers across multiple disciplines, as evidenced by his numerous co-authored publications spanning virology, immunology, hepatology, and clinical diagnostics. His work has appeared in high-impact journals including Nature Communications, Journal of Hepatology, and Hepatology.
Sophie Debrock is an Associate Professor at the Department of Development and Regeneration within the Faculty of Medicine at KU Leuven . Her work focuses on genomic instability, chromosomal dynamics, and single-cell multi-omics in human embryogenesis. Current projects include spatial (multi-)omics assays for embryo development (2020–2025) Developed innovative embryo selection protocols for assisted reproduction (2019–2025) Expert in single-cell DNA/RNA sequencing and 3D nuclear architecture analysis Research Trends : Recent publications highlight her expertise in genomic profiling, epigenetic alterations, and clinical applications of single-cell technologies. Key themes include chromosomal instability , preimplantation genetic testing , and embryo developmental heterogeneity .
Dr. Anja Feldmann serves as the Head of the Radioimmunology Department at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR). She leads research in cancer immunotherapy, focusing on modular and switchable CAR T-cell platforms for targeted treatment of solid tumors and hematological malignancies. Her work integrates cutting-edge technologies like biosensors and theranostic tools to enhance therapeutic efficacy and overcome immune escape mechanisms. Her research interests revolve around developing universal chimeric antigen receptor (UniCAR) systems and their adaptability for personalized immunotherapy. Key areas include the design of target modules for CAR T/NK cells, combining immunotherapy with radiation, and creating diagnostic tools such as extended-gate field-effect transistors (FET) biosensors to monitor drug responses. She also explores applications in autoimmune diseases and oncology, emphasizing safety and precision in therapeutic approaches. Dr. Feldmann’s recent advancements include overcoming antigen loss in tumors via dual targeting and improving CAR T-cell persistence through affinity optimization. Her lab’s work on RevCAR systems demonstrates innovation in redirecting T cells to immunosuppressive markers like PD-L1, turning them into activating signals. Despite no explicit mention of scientific awards, her contributions to CAR T-cell engineering and theranostics are highlighted through collaborations and preclinical studies. She oversees projects involving clinical scale manufacturing, off-the-shelf NK cell therapies, and interdisciplinary approaches to cancer management. Her team’s efforts span from lab-scale innovations to translational research, aiming to bridge gaps between diagnostics and treatment.
Dr. Jeremy Allred serves as an Assistant Professor of Medicine within the Division of Hematology, Oncology, and Transplantation at the University of Minnesota School of Medicine. His clinical and research activities focus on advancing therapeutic strategies for hematologic malignancies and improving outcomes in stem cell transplantation, with particular emphasis on translational applications of cellular therapies and immune modulation. Dr. Allred's research program centers on acute myeloid leukemia (especially TP53-mutated subtypes), graft-versus-host disease mechanisms, and innovative immunotherapies including CAR T-cell treatments. His work investigates genetic determinants of treatment response, strategies to mitigate therapy-related toxicities like neurotoxicity, and the application of induced pluripotent stem cell technologies for immune cell generation. Key interests include VISTA immune checkpoint biology, sarcopenia assessment in transplant recipients, and optimizing salvage therapies for high-risk leukemia patients. Analysis of Dr. Allred's publication record (2015-2025) reveals a consistent trajectory in translational hematology/oncology research with growing emphasis on cellular therapies and immune regulation. His recent work demonstrates increasing focus on TP53-mutated AML therapeutics, GVHD prevention through novel immune checkpoints, and practical management of CAR T-cell complications. The publications collectively show progression from basic hematopoiesis mechanisms toward clinically applicable interventions in transplantation and immunotherapy, with significant contributions to understanding treatment sequencing in secondary leukemias and stem cell-derived immune cell engineering.
Paul Stothard is a Professor at the University of Alberta, affiliated with the Faculty of Agricultural, Life and Environmental Sciences and the Department of Agriculture, Food & Nutrition Science. He leads the Stothard Research Group, which focuses on bioinformatics-driven genomics and genetics research. His academic work integrates software development with applied animal genetics, contributing to breeding strategies for cattle and pigs, as well as environmental and microbial genomic projects. Dr. Stothard holds a PhD in molecular biology and genetics from the University of Alberta. His research interests include identifying genetic bases for animal traits, cataloging genome variations in livestock, developing diagnostic tools for pathogens in feedlot cattle, and creating user-friendly bioinformatics resources like Proksee and the CGView Comparison Tool. His group’s findings have been applied in DNA tests for cattle breeding and SNP chips for bison conservation. He is currently involved in the Bison Integrated Genomics (BIG) Project and the Resilient Dairy Genome Project, funded by Genome Canada and collaborating with institutions like the University of Guelph. His software contributions include Proksee (a bacterial genome analysis server) and CGView, widely used in microbial genomics research. Teaching includes courses such as AFNS 508 (Applied Bioinformatics) and AN SC 485 (Animal Genetics and Breeding). He advises students like Natalie Diether, who received the 2023 ALES Graduate Student PhD Thesis Award. His research also addresses antimicrobial resistance, feed efficiency in dairy cows, and the genetic underpinnings of livestock resilience to disease and environmental stress.
Leonard Shultz is a Professor at the University of Maine Graduate School of Biomedical Science and Engineering. His research focuses on the development and application of humanized SCID mice for translational biomedical research, particularly in immunodeficiency diseases, autoimmunity, and hematological disorders. He has pioneered mouse models like the NOD/SCID/IL2rγ null strain to study human immune system development and disease mechanisms. Education: PhD in Immunology from the University of Massachusetts (1972). Shultz’s work leverages genetically engineered mouse models to investigate diabetes, bone development, anemia, thrombocytopenia, infectious diseases , and transplantation tolerance . His research has significant implications for regenerative medicine and preclinical testing of therapies. In 2010, he identified the Abcg5 gene mutation in the trac mouse model, linking elevated plant sterols to thrombocytopenia and cardiomyopathy , mirroring human Mediterranean Macrothrombocytopenia . This discovery established a critical single-gene model for studying sterol-related hematological and cardiovascular pathologies. His publications from 2008–2011 highlight interdisciplinary applications of humanized mice in leukemia stem cell research, HIV-1 gene editing, dengue virus studies , and solid tumor xenografts . Collaborations span institutions like the University of Massachusetts Medical School and Riken Research Center for Allergy and Immunology.
Prof. Ionel Mangalagiu serves as Professor at the Department of Exact and Natural Sciences, Alexandru Ioan Cuza University, Iași, Romania, and leads research at the CERNESIM Center. His career spans over two decades with continuous contributions to heterocyclic chemistry, maintaining active publication and grant leadership through 2025. His research program integrates three interconnected domains: Chemistry and Health : Design of azaheterocyclic compounds as potential drugs for cancer, HIV, tuberculosis, and antimicrobial applications, including Alzheimer's disease treatment and agricultural growth factors. Chemistry and Nanosciences : Development of fluorescent nanomaterials, molecular logic gates, chemosensors, and azacryptands for optoelectronic applications. Chemistry and Environment : Pioneering eco-friendly synthesis using microwaves and ultrasound to minimize environmental impact while maintaining reaction efficiency. His methodology combines organic synthesis, computational modeling, and biological validation. Analysis of recent publications (2023-2025) reveals a strategic shift toward hybrid heterocyclic architectures with dual anticancer-antimicrobial functionality. Key trends include the dominance of indolizine, phenanthridine, and diazine scaffolds, systematic application of green synthesis protocols, and exploitation of fluorescent properties for sensing applications. Computational tools increasingly guide molecular design and activity prediction. Prof. Mangalagiu has secured 12 major research projects totaling over 1.5 million Euros from NATO, EU FP7, COST, and Romanian funding agencies. These initiatives address antimicrobial resistance (CED-Antim project), nanomaterials for medical devices (NanoTP), and sustainable chemistry (Synthesis of Highly Fluorescent Materials). While specific student names aren't listed, his grant leadership implies extensive mentorship in synthetic chemistry and drug discovery. His laboratory operates within the CERNESIM Center, which provides advanced infrastructure for heterocyclic synthesis, nanomaterials characterization, and biological testing. The center maintains active collaborations with European research institutions under Horizon 2020 frameworks, focusing on translating chemical innovations into pharmaceutical and environmental applications.
W. Christopher Ehmann is a Professor in the Division of Hematology and Oncology at the Pennsylvania State University College of Medicine , affiliated with the Penn State Cancer Institute . His work focuses on improving outcomes for patients with hematological malignancies through stem cell transplantation and immunological interventions. Key Research Areas : Allogeneic Hematopoietic Stem Cell Transplantation, Graft-versus-Host Disease (GvHD), Donor Lymphocyte Infusion, Chimerism, Cyclophosphamide, and Mantle Cell Lymphoma. Recent studies (2024–2025) highlight his focus on optimizing donor lymphocyte infusion outcomes in relapsed hematological malignancies, leveraging post-transplant cyclophosphamide to mitigate graft failure, and refining chimerism testing for early leukemia relapse detection. His collaborations span institutions, addressing challenges like multi-lineage cytopenia and recurrent disease in aplastic anemia.
Myles Nickolich is an Associate Professor at the Penn State University College of Medicine and serves as the Assistant Dean for Education in the Clinical Learning Environment. His research focuses on Hematology , Oncology , and Stem Cell Transplantation , particularly in improving outcomes for patients with hematological malignancies. Institution: Penn State University School: College of Medicine Department: Department of Medicine, Division of Hematology and Oncology Academic Rank: Associate Professor His work emphasizes Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) , Graft-versus-host Disease , and Leukemia Relapse prevention. Recent studies explore the role of Post-transplant Cyclophosphamide and Chimerism Testing in managing transplant complications. Scientific Awards: Dean's Award for Excellence in Teaching (2021) Dr. Nickolich's research trends highlight advancements in Transplantation Medicine , Immunotherapy , and Diagnostic Oncology . His collaborations span institutions and focus on improving survival rates and reducing relapse risks post-transplantation.
Lee Ann Baxter-Lowe, PhD, is a Clinical Professor of Pathology at the University of Southern California (USC). She serves as the Chair of the Histocompatibility Committee of the United Network for Organ Sharing (UNOS) and facilitates the Histocompatibility Workgroup for the 2012 National Consensus Conference on Kidney Paired Donation (KPD). Her research focuses on HLA polymorphism and its role in transplantation and human disease, particularly investigating HLA antibodies in solid organs and hematopoietic stem cell transplants. She has led over 125 publications and directed a lab supporting NIH-funded clinical trials. Her work emphasizes advancing histocompatibility testing and policy development in transplantation. Her research spans HLA typing methodologies, donor-recipient compatibility, and outcomes analysis in hematopoietic cell and organ transplantation. Key contributions include identifying permissible HLA mismatches, evaluating high-resolution typing’s impact on kidney transplants, and developing scoring systems for transplant ranking. She has contributed to multicenter studies like the Cord Blood Transplantation Study (COBLT) and serves on national/international committees advancing transplant policies. Dr. Baxter-Lowe’s publications highlight advancements in digital PCR, cell-free DNA biomarkers, and transplant-related immune responses. Her lab has been a core facility for the NIH Immune Tolerance Network, emphasizing translational research. She has advised clinical trials in pediatric and adult patients, focusing on novel conditioning regimens and immunochemotherapy. Her leadership roles in UNOS and other organizations reflect her dedication to policy development in transplant medicine. She has addressed disparities in donor availability for African American patients and optimized transplant outcomes through HLA typing innovations.
Professor José Rafael Penadés is a Professor at the Department of Infectious Disease, Imperial College London, and a Lecturer at CEU Cardenal Herrera University. His work focuses on bacterial gene transfer mechanisms, antimicrobial resistance, and leveraging AI to accelerate scientific discovery. He leads a team that tested Google’s AI co-scientist platform, which successfully generated hypotheses matching his group’s unpublished research on viral satellites and bacterial species boundaries. His research explores how satellite viruses use viral tails to infect diverse bacterial species, a mechanism critical for bacterial evolution and antibiotic resistance. Collaborations include Imperial College, CEU UCH, and the Instituto de Biomedicina de Valencia (IBV). Prof Penadés emphasizes AI’s potential to revolutionize hypothesis generation, reducing experimental timelines and addressing global healthcare challenges like antimicrobial resistance. The team’s findings on chimeric infective particles and AI-driven research were published in a high-impact pre-print study.
Katarzyna Grzyb is a Lecturer in the Department of Molecular Biology of Viruses at the University of Gdańsk. Her research focuses on developing novel vaccine platforms against viral pathogens, particularly hepatitis C virus (HCV) and norovirus. Research highlights: Development of chimeric HBV-HCV virus-like particles (VLPs) for vaccine delivery Minicircle DNA vaccine designs for enhanced T-cell responses Leishmania tarentolae expression system for norovirus VLP production Analysis of glycan modifications on antibody neutralization efficiency Her work bridges virology and immunology, with recent publications exploring SARS-CoV-2 neutralization assays and HCV epitope-specific antibody responses.
James M. Burns Jr., PhD, is a Professor in the Department of Microbiology & Immunology at Drexel University College of Medicine. His research program focuses on malaria vaccine development, particularly on improving subunit vaccines targeting multiple stages of the Plasmodium parasite life cycle. Dr. Burns earned his PhD from Hahnemann University in 1989. His laboratory investigates the host immune response to malaria parasites and develops highly immunogenic, multi-subunit, multi-stage vaccines. His work bridges basic research using rodent malaria models with translational studies focused on human malaria. Primary Research Focus: Development of protective immunity against malaria induced by immunization with defined subunit vaccines targeting pre-erythrocytic stage, blood-stage and sexual stage parasites Current Projects: Evaluating vaccine candidates including merozoite surface protein 2 (PfMSP2), reticulocyte-binding protein homologue 5 (PfRh5), the 25 kDa sexual stage antigen (Pfs25), and circumsporozoite protein Methodology: Utilizing Plasmodium yoelii and Plasmodium chabaudi rodent models alongside in vitro studies of P. falciparum blood-stage parasites Dr. Burns' publication record shows consistent productivity with research spanning from fundamental parasite biology to advanced vaccine development. His recent work (2020-2024) demonstrates continued innovation in malaria vaccine design, particularly in developing chimeric antigens and multi-stage vaccine formulations. His research addresses two critical challenges in malaria vaccinology: improving subunit vaccine immunogenicity and developing multi-antigen formulations without compromising individual component efficacy. Scientific Recognition: Institutional Service Award, Drexel University College of Medicine (2023) Dr. Burns has mentored graduate students including Hayley Klingenberg and research associates like Amy Ott, PhD. His laboratory has made significant contributions to understanding how to enhance the immunogenicity of malaria vaccine candidates through innovative approaches such as engineering parasite-specific carrier proteins. His work provides a solid foundation for subsequent safety and immunogenicity testing in human subjects, potentially leading to a combined pre-erythrocytic-stage/blood-stage/sexual-stage malaria vaccine that could reduce clinical disease severity and block transmission.
